Synopsys, Inc. (NASDAQ:SNPS) was the target of unusually large options trading activity on Monday. Traders purchased 3,234 call options on the stock. This represents an increase of 1,370% compared to the typical daily volume of 220 call options.
Synopsys (SNPS) traded up $1.12 during trading on Wednesday, hitting $86.62. 1,289,392 shares of the stock traded hands, compared to its average volume of 990,858. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market cap of $12,689.74, a PE ratio of 100.59, a P/E/G ratio of 3.80 and a beta of 1.04. Synopsys has a 12-month low of $65.56 and a 12-month high of $94.80.
Synopsys (NASDAQ:SNPS) last posted its quarterly earnings data on Wednesday, November 29th. The semiconductor company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.12. The firm had revenue of $696.60 million for the quarter, compared to analysts’ expectations of $650.72 million. Synopsys had a net margin of 5.01% and a return on equity of 5.78%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the company posted $0.77 EPS. equities research analysts forecast that Synopsys will post 2.24 EPS for the current year.
In other Synopsys news, Director Chrysostomos L. Nikias sold 21,074 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $89.78, for a total value of $1,892,023.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven Walske sold 4,545 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $90.12, for a total transaction of $409,595.40. Following the completion of the sale, the director now owns 14,988 shares in the company, valued at $1,350,718.56. The disclosure for this sale can be found here. Insiders sold a total of 65,442 shares of company stock worth $5,779,693 over the last quarter. Corporate insiders own 1.82% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Cerebellum GP LLC purchased a new stake in shares of Synopsys during the 4th quarter valued at $124,000. Robecosam AG grew its holdings in shares of Synopsys by 69.2% during the 4th quarter. Robecosam AG now owns 2,200 shares of the semiconductor company’s stock valued at $188,000 after purchasing an additional 900 shares during the last quarter. Calton & Associates Inc. bought a new position in shares of Synopsys during the 4th quarter valued at $217,000. IBM Retirement Fund bought a new position in shares of Synopsys during the 4th quarter valued at $201,000. Finally, Conning Inc. bought a new position in shares of Synopsys during the 4th quarter valued at $205,000. Hedge funds and other institutional investors own 89.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/14/synopsys-target-of-unusually-large-options-trading-snps.html.
Synopsys, Inc provides software, intellectual property (IP) and services. The Company supplies the electronic design automation (EDA) software that engineers use to design and test integrated circuits, also known as chips. It also offers IP products, which are pre-designed circuits that engineers use as components of larger chip designs rather than designing those circuits themselves.
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.